

TABLE OF CONTENTS

3	NCI BUDGET FACT BOOK
6	NCI BUDGET SUMMARY DATA
6	Most Recent Reported Fiscal Year Budget
7	Funding Allocated to Major NCI Program Areas
8	Extramural Funding
10	Obligations by Budget Mechanism and Division
28	NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent
31	Special Sources of Funds
36	Funding for Research Areas
38	NCI EXTRAMURAL PROGRAMS
38	Research Project Grants (RPGs)
48	Grants to NCI-Designated Cancer Centers
56	Specialized Programs of Research Excellence (SPOREs)
59	National Research Service Awards (NRSA)
60	Research Career Awards "K" Program
62	Grant and Contract Awards
66	NCI HISTORICAL TRENDS
66	Bypass Budget Requests and NCI Appropriations
71	NCI Funding Trends
74	Extramural vs Intramural and RMS Funding
77	Comparison of Dollars, Positions, and Space
78	NCI Personnel
79	NCI and NIH AIDS Funding History
80	CANCER MOONSHOTSM - RECENT FISCAL YEAR FUNDING
81	Obligations by Budget Mechanism
84	Funding by Research Category

NCI Budget Fact Book

This year's Budget Fact Book provides a summary of the distribution of the Fiscal Year 2019 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms. NCI funding policies related to research grant awards are also provided.

FISCAL YEAR 2019 HIGHLIGHTS

Funds available to the NCI totaled \$6.01 billion, post inter-departmental and intra-NIH transfers. This reflects an increase of 1.1% and \$67.3 million from the previous fiscal year.&

- The 21st Century Cures Act, which was signed into law in December 2016, authorized \$1.8 billion to fund the Cancer Moonshot over a 7-year period. The Cancer Moonshot funding received during Fiscal Year 2019 totaled \$400 million.
- Of the total NCI budget obligated, 42.4% of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 4,984 (including grants funded through the Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) programs).
- Over one-fourth of the RPGs awarded were new ("Type 1") or competing renewal ("Type 2") awards.
- There was a total of 1,178 competing RPGs funded (excluding grants funded through SBIR & STTR).
- Almost one-third of the total NCI budget supported ongoing, non-competing ("Type 5") RPGs.
- The R01 grants were funded to the 8th percentile for Experienced and New Investigators and the Early Stage Investigators were funded to the 14th percentile.
- R01 Early Stage Investigators between the 1st and 9th percentiles were converted to R37 awards giving them the opportunity to extend their research an additional 2 years.
- SBIR & STTR awards funded 245 grants totaling \$136.7 million.
- Intramural Research comprised 16.1% of the total NCI budget.&

The dollar amounts displayed in the NCI Budget Fact Book represent direct appropriated funds only, unless otherwise denoted.


Where to Find Information from Previous Fact Books

Information provided in previous Fact Books can now be found online. For example, view NCI's Organization Chart on the NIH Office of Management Assessment website. Cancer statistics can be found on the NCI website, as well as more detailed NCI Organization information. A limited number of Fact Books from prior years are available as hardcopy publications through the NCI Publications Locator. Find PDFs of all the NCI Budget Fact Books, dating back to 1971.

The NCI Budget Fact Book data is organized into the following sections. If you have any questions, please contact the Office of Budget and Finance (OBF).&

NATIONAL CANCER INSTITUTE

Budget At A Glance: Fiscal Year 2019



NCI BUDGET
INCREASED BY
\$67.3 MILLION
(1.1%) FROM FISCAL
YEAR 2018

42.4%

OF THE TOTAL

NCI BUDGET

ALLOCATED FOR

RESEARCH

PROJECT GRANTS


THE NATIONAL CANCER INSTITUTE (NCI) PROVIDES FUNDING AND SUPPORT FOR HEALTH-RELATED RESEARCH AND DEVELOPMENT THROUGH THE RPG (R01) GRANT MECHANISM.



RO1 EARLY STAGE
INVESTIGATORS BETWEEN
THE 1ST AND 9TH
PERCENTILES WERE
CONVERTED TO R37
AWARDS GIVING THEM
THE OPPORTUNITY TO
EXTEND THEIR RESEARCH
AN ADDITIONAL 2 YEARS.



OF RPG AWARDS WERE NEW (TYPE 1) OR COMPETING RENEWAL (TYPE 2) AWARDS



OF THE TOTAL
NCI BUDGET
SUPPORTED
ONGOING,
NON-COMPETING
(TYPE 5) RPGs

1,178

NCI-FUNDED COMPETING RPGs



TOTALING OVER \$136.7 MILLION FUNDED AS SMALL BUSINESS INNOVATION RESEARCH (SBIR) AND SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) AWARDS. 4,984

TOTAL NCI-FUNDED RPGs (INCLUDING SBIR & STTR)

cancer.govSource: 2019 NCI Budget Fact Book

NCI Budget Summary Data

This section of the NCI Budget Fact Book provides data about funds available to NCI and information on how NCI obligated its funding.

Most Recent Reported Fiscal Year Budget

In FY 2019, Congress passed an Omnibus that appropriated \$5.744 billion for NCI. NCI was also appropriated \$400 million in FY 2019 as a result of the 21st Century Cures Act. After permissive transfers, \$6.121 billion was available to NCI to obligate.

In addition to the appropriated amount for the fiscal year, NCI entered into inter- and intra-agency agreements with other Federal agencies and NIH institutes and centers (ICs). These agreements often provide reimbursements for materials, supplies, equipment, work, or services to assist other agencies and ICs accomplish their missions.

FISCAL YEAR 2019T BUDGET

Actual Obligations Resulting From Appropriated Funds	FY 2019 Amount
FY 2019 Appropriation	\$5,743,892,000
FY 2019 Cancer Moonsot Appropriation	\$400,000,000
Transfer under the HHS Secretary's transfer authority	-19,730,000
Transfer from NIH Office of AIDS Research&	-2,874,000
Lapse	-252,785
Cancer Moonshot Carryover	-\$128,745,306
Actual Obligations Subtotal	\$5,992,289,909
Reimbursable Obligations	\$22,479,171
Total FY 2019 NCI Obligations	\$5,992,289,909

Funding Allocated to Major NCI Program Areas

Each fiscal year, NCI and other NIH institutes and centers report their obligations by mechanism. In addition to reporting by mechanism, reporting obligations by program structure is another way of showing how NCI obligates its funding each fiscal year.&

For the purposes of reporting by program structure, NCI programs are categorized by budget activity. These budget activities include:

- Research categorized by the following research thrusts: cancer causation; detection and diagnosis; treatment; cancer biology
- Resource Development cancer centers, research manpower development, and buildings and facilities
- Cancer Prevention and Control
- Program Management and Support



^{*}Includes FY 2019 Cures-Moonshot funding.


^{*}Excludes FY 2018 and FY 2017 Cures-Moonshot carryover obligations.

Extramural Funding

Overall, NCI obligations for its extramural program, which includes grants and contracts, totaled \$4.58 billion in FY 2019.

- Obligations for grants totaled approximately 82.8% of extramural funding&
- Obligations for contracts totaled approximately 17.2% of extramural funding&
- Overall, extramural obligations amounted to approximately 76.4% of the NCI budget in FY 2019&

Obligations on this page include FY 2019 Cancer Moonshot funding and excludes FY 2017 and FY 2018 Cures Moonshot carryover obligations.




EXTRAMURAL FUNDS, FISCAL YEAR 2019

Mechanism	Amount	Percent
Research & Development (R&D) Contracts	\$768,095,181	16.8%&
Buildings and Facilities	18,000,000	0.4%&
Construction Contracts	0	0.0%&
Subtotal Contracts	\$786,095,181	17.2%
Research Project Grants (RPGs)	2,541,699,571	55.5%&
Cancer Centers/Specialized Centers/SPORES	655,966,379	14.3%&
NRSA	86,977,607	1.9%&
Other Research Grants	506,763,422	11.1%&
Subtotal Grants	\$3,791,406,979	82.8%
Total Extramural Funds	\$4,577,502,160	100.0%
Intramural/RMS Funds		1,414,787,748
Total NCI		\$5,992,289,908

Obligations by Budget Mechanism and Division

All NIH Institutes and Centers report their actual obligations each fiscal year by budget mechanism. The tables below display NCI funding by mechanism and division. The number of awards, trainees, or employees for each mechanism, as well as the dollar amount and percent share of the total NCI budget for each funding mechanism is also included.

NCI Obligations by Mechanism



Other Research mechanisms includes the following grants: Career Programs (K Awards), Cancer Education, Clinical Cooperative Groups, Pre-Doc Post-Doc Transition Awards, Minority Biomedical Research Support, Research Pathway in Residency, Resource Grants, International Research Training grants, Cooperative Conference Agreements, and Conference grants.

All items in italics are non add entries.

^{*}Includes FY 2019 Cures-Moonshot funding.

^{*}Excludes FY 2018 and FY 2017 Cures-Moonshot carryover obligations.

NCI OBLIGATIONS

NCI Obligations by Mechanism, FY 2019 (Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
	Non-Competing	3,561	\$1,801,598,229	30.1%&
	Administrative Supplements	268	30,715,356	0.5%&
	Competing	1,178	572,715,679	9.6%&
Research Project Grants (RPGs)	Subtotal, without SBIR/STTR Grants	4,739	\$2,405,029,255	40.1%
	SBIR/STTR Grants	245	136,670,316	2.3%&
	Subtotal, RPGs	4,984	\$2,541,699,571	42.4%
	Cancer Centers Grants-P20/P30	89	337,081,712	5.6%&
	SPOREs-P50	53	112,795,999	1.9%&
Centers & SPOREs	Other P50s/P20s	6	7,423,937	0.1%&
	Other Specialized Centers	103	198,664,731	3.3%&
	Subtotal, Centers	251	\$655,966,379	10.9%
	Career Program			0.0%&
Other Research	Post-Doc-Fellow Awards-K00	52	4,480,191	0.1%&

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
	Temin & Minority Mentored Awards-K01/K43	33	5,346,036	0.1%&
	Estab. Inv. Award-K-05	2	172,247	0.0%&
	Preventive Oncology-K07	64	9,916,207	0.2%&
	Clinical Investigator-K08	152	30,547,484	0.5%&
	Clinical Oncology-K12	21	15,653,263	0.3%&
Other Research	Transitional Career Development-K22	52	9,353,712	0.2%&
	Mentored Patient Oriented RCDA-K23	10	1,688,518	0.0%&
	Mid-Career Invest. & Patient Orient. Res-K24	9	1,512,698	0.0%&
	Mentored Quant. Res Career-K25	4	569,778	0.0%&
	Mentored Career Devel/Tem Intl Career-K43	0	233,370	0.0%&
	Pathway to Independence Awards K99	47	5,517,800	0.1%&

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
	Subtotal, Career Program	446	\$84,991,304	1.4%
	Cancer Education Program-R25 (including BD2K)	77	20,459,296	0.3%&
	Clinical Cooperative Groups-U10/UG1	104	290,137,118	4.8%&
	PreDoc PostDoc Transition Awards-F99	46	1,827,785	0.0%&
	Minority Biomedical Support-S06	0	96,830	0.0%&
Other Research	Research Pathway in Residency-R38	1	358,020	0.0%&
	Resource Grants-R24/U24	0	1,839,210	0.0%&
	Int'l Rsrch Training Grants Conference- D43/U2R	84	104,979,535	1.8%&
	Cooperative Conference Agreements-U13	60	814,205	0.0%&
	Conference Grants-R13	0	1,260,119	0.0%&

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
Other Research	Subtotal, Career and Other Research Grants	818	\$506,763,422	8.5%
Subtotal, Research Grants		6,053	\$3,704,429,372	61.8%
National Research Service Award (NRSA) Fellowships	Trainees	1,589	86,977,607	1.5%&
	R&D Contracts	365	630,327,168	10.5%&
	SBIR Contracts	49	34,200,374	0.6%&
R&D Contracts	NIH Management Fund/SSF Assessment		103,567,638	1.7%&
	Subtotal, Contracts	365	\$768,095,181	12.8%
	Program		740,140,813	12.4%&
Intramural Research	NIH Management Fund/SSF Assessment		224,759,956	3.8%&
	Subtotal, Intramural Research (FTEs)	1,683	\$964,900,769	16.1%
Research Management & Support (RMS)	Research Management and Support (RMS)		340,979,062	5.7%&

Type of Mechanism	Mechanism	Number	Amount	% of Total Amount
	SBIR RMS		2,999,998	0.1%&
Research Management & Support (RMS)	NIH Management Fund/SSF Assessment		105,907,919	1.8%&
	Subtotal, RMS (FTEs)	1,205	\$449,886,979	7.5%
Buildings & Facilities			18,000,000	0.3%&
Total NCI	(FTEs)	2,888	\$5,992,289,908	100.0%

Division Obligations by Mechanism

DIVISION OBLIGATIONS

Total Division Obligations, FY 2019

(Whole Dollars)

Division	Total
Center for Cancer Research (CCR)	\$459,131,797
Division of Cancer Epidemiology and Genetics (DCEG)	107,599,892
Division of Cancer Treatment and Diagnosis (DCTD)	556,649,579
Division of Cancer Biology (DCB)	118,694,263
Division of Cancer Control and Population Sciences (DCCPS)	131,479,316
Division of Cancer Prevention (DCP)	216,976,942
Division of Extramural Activities (DEA)	21,485,349
Office of the Director (OD)&	1,540,365,858
Total Division	\$5,471,869,090

CENTER FOR CANCER RESEARCH (CCR)

CCR Obligations

Type of Mechanism	Mechanism	Amount
Intramural Research	Program NIH Management Fund	\$459,131,797 0
Total CCR		\$459,131,797

DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS (DCEG)

DCEG Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
R&D Contracts	R&D Contracts	\$23,889,478
NAD CONTRACTS	SBIR Contracts	0
Intramural Research	Program	83,710,414
Intramurar Research	NIH Management Fund	0
Total DCEG		\$107,599,892

DIVISION OF CANCER TREATMENT AND DIAGNOSIS (DCTD)

DCTD Obligations

Type of Mechanism	Mechanism	Amount
	Cancer Centers Grants-P20/ P30	\$0
	SPOREs-P50	112,524,394
Centers & SPOREs	Other P50s/P20s	123,600
	Other Specialized Centers	40,979,809
	Subtotal, Centers	\$153,627,803
Other Research–Grants	Cancer Education Program-R25	0
Other Research-Grants	Clinical Cooperative Groups-U10/UG1	155,686,039

Type of Mechanism	Mechanism	Amount
	Minority Biomedical Support-S06	0
	Sci Eval-U09/T09 & Rsch Enhance-SC1	0
	Continuing Education	0
Other Research–Grants	Resource Grants-R24/U24	6,218,137
Other Research-Grants	Explor Coop Agreement-U56	0
	Global Infect. Disease Rsrch Training Prog - D43	0
	Conference Grants-R13/U13	0
	Subtotal, Other Research- Grants	\$161,904,176
Subtotal, Research Grants		\$315,531,979
	R&D Contracts	185,825,143
R&D Contracts	SBIR Contracts	0
	Subtotal, Contracts	\$185,825,143
	RMS	55,292,457
Research Management & Support (RMS)	SBIR RMS	0
	NIH Management Fund	0
	Subtotal, RMS	\$55,292,457

DIVISION OF CANCER BIOLOGY (DCB)

DCB Obligations

Type of Mechanism	Mechanism	Amount
	Cancer Centers Grants-P20/ P30	\$0
	SPOREs-P50	0
Centers & SPOREs	Other P50s/P20s	0
	Other Specialized Centers	99,436,005
	Subtotal, Centers	\$99,436,005
	R&D Contracts	481,675
	SBIR Contracts	0
R&D Contracts	NIH Management Fund/SSF Assessment	0
	Subtotal, Contracts	\$481,675
Other Research–Grants	Subtotal, Other Research– Grants	\$6,507,275
	RMS	12,269,308
Research Management & Support (RMS)	SBIR RMS	0
	NIH Management Fund	0
	Subtotal, RMS	\$12,269,308
Total DCB		\$118,694,263

DIVISION OF CANCER CONTROL AND POPULATION SCIENCES (DCCPS)

DCCPS Obligations

Type of Mechanism	Mechanism	Amount
	Cancer Centers Grants-P20/ P30	\$0
	SPOREs-P50	0
	Other P50s/P20s	7,300,337
	Other Specialized Centers	475,000
	Subtotal, Contracts	\$7,775,337
	Cancer Education Program-R25	
	Clinical Cooperative Groups-U10/UG1	
Centers & SPOREs	PreDoc PostDoc Transition Awards-F99	
	Minority Biomedical Support-S06	
	Research Pathway in Residency-R38	
	Resource Grants-R24/U24/ U2C	1,155,426
	Global Infect. Disease Rsrch Training Prog - D43/U2R	
	Cooperative Conference Agreements-U13	
	Conference Grants-R13	

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Subtotal, Other Research Grants	\$1,155,426
	Subtotal, Research Grants	\$8,930,763
R&D Contracts	R&D Contracts	86,108,790
	SBIR Contracts	0
	Subtotal, Contracts	\$86,108,790
Research Management & Support (RMS)	RMS	36,439,763
	SBIR RMS	0
	NIH Management Fund	0
	Subtotal, RMS	\$36,439,763
Total DCCPS		\$131,479,316

DIVISION OF CANCER PREVENTION (DCP)

DCP Obligations

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Cancer Centers Grants-P20/ P30	\$0
	SPOREs-P50	0
	Other P50s/P20s	0
	Other Specialized Centers	7,132,805

Type of Mechanism	Mechanism	Amount
Centers & SPOREs	Subtotal, Centers	\$7,132,805
	Cancer Education Program-R25	0
	Clinical Cooperative Groups-U10/UG1	128,308,872
	Minority Biomedical Support-S06	0
	Sci Eval-U09/T09 & Rsch Enhance-SC1	0
Other Research–Grants	Continuing Education	0
	Resource Grants-R24/U24	0
	Explor Coop Agreement-U56	0
	Global Infect. Disease Rsrch Training Prog - D43	0
	Conference Grants-R13/U13	0
	Subtotal, Other Research Grants	\$128,308,872
Subtotal, Research Grants		\$135,441,677
R&D Contracts	R&D Contracts	56,374,048
	SBIR Contracts	0
	Subtotal, Contracts	\$56,374,048
Research Management & Support (RMS)	RMS	25,161,217

Type of Mechanism	Mechanism	Amount
Research Management & Support (RMS)	SBIR RMS	0
	NIH Management Fund	0
	Subtotal, RMS	\$25,161,217
Total DCP		\$216,976,942

DIVISION OF EXTRAMURAL ACTIVITIES (DEA)

DEA Obligations

(Whole Dollars)

Type of Mechanism	Mechanism	Amount
	RMS	\$21,485,349
Research Management & Support (RMS)	SBIR RMS	0
	NIH Management Fund	0
Total DEA		\$21,485,349

OFFICE OF THE DIRECTOR (OD)

OD Obligations

Type of Mechanism	Mechanism	Amount
Research Project Grants (RPGs)	Non-Competing	\$0
	Administrative Supplements	0

Type of Mechanism	Mechanism	Amount
Research Project Grants (RPGs)	Competing	0
	Subtotal, without SBIR/ STTR Grants	\$0
	SBIR/STTR Grants	136,670,316
	Subtotal, RPGs	\$136,670,316
	Cancer Centers Grants-P20/ P30	337,081,712
	SPOREs-P50	271,605
Centers & SPOREs	Other P50s/P20s	0
	Other Specialized Centers	50,641,112
	Subtotal, Centers	\$387,994,429
	Career Program	0
	Post-Doc-Fellow Awards-K00	4,480,191
Other Research–Career Program	Temin & Minority Mentored Awards-K01	5,346,036
	Estab. Inv. Award-K05	172,247
	Preventive Oncology-K07	9,916,207
	Clinical Investigator-K08	30,547,484
	Clinical Oncology-K12	15,653,263
	Transitional Career Development-K22	9,353,712

Type of Mechanism	Mechanism	Amount
	Mentored Patient Oriented RCDA-K23	1,688,518
	Mid-Career Invest. & Patient Orient. Res-K24	1,512,698
Other Research–Career Program	Mentored Quant. Res Career-K25	569,778
	Mentored Career Devel/Tem Intl Career-K43	233,370
	Pathway Award-K99	5,517,800
	Subtotal, Career Program	\$84,991,304
	Cancer Education Program-R25	20,459,296
	Clinical Cooperative Groups-U10/UG1	6,142,207
	PreDoc PostDoc Transition Awards-F99	1,827,785
Other Research–Grants	Minority Biomedical Support-S06	96,830
	Rsrch Pathway in Residency (938)	358,020
	Pilot Research Project-OT2	1,839,210
	Resource Grants-R24/U24	91,098,697
	Conference Grants-R13/U13	814,205

Type of Mechanism	Mechanism	Amount
	Int'l Research Training Grants-D43/U2R	
Other Research–Grants	Int'l Research Training Grants-D43/U2R	1,260,119
Other Research-Grants	Subtotal, Other Research– Grants	\$123,896,369
Subtotal, Research Grants		\$733,552,418
NRSA Fellowships		86,335,463
	R&D Contracts	277,648,035
	SBIR Contracts	34,200,374
R&D Contracts	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	Subtotal, Contracts	\$311,848,409
	Program	197,298,602
Intramural Research	NIH Management Fund/ SSF Assessment/Program Evaluation	0
	Subtotal, Intramural Research	\$197,298,602
December Management & Comment (DMC)	RMS	190,330,968
Research Management & Support (RMS)	SBIR RMS	2,999,998

Type of Mechanism	Mechanism	Amount	
Research Management & Support (RMS)	NIH Management Fund/ SSF Assessment/Program Evaluation	0	
	Subtotal, RMS	\$193,339,966	
Buildings and Facilities		18,000,000	
Total OD		\$1,540,365,858	

NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, social work, drug costs, red team response, bench to bedside and the Children's Hospital increase for FY19.


Center for Scientific Review: Initial scientific review of applications and assignment of research grant applications to institutes.

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services.

Service & Supply Fund: Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, biomedical engineering, and GSA rental payments for space (to include all building rental costs, including utilities and guard services).

The chart and table below show the distribution of NCI's payment for these common activities and NCI's share as a percent of NIH total.



NIH MANAGEMENT FUND, SSF, AND GSA RENT FY 2019

(Whole Dollars)

Distribution of NCI Payment	Amount	Share of NCI
Clinical Center	\$146,225,820	37.0%&
Center for Scientific Review&	26,444,914	6.7%&
Center for Information Technology	30,690,142	7.8%&
Service & Supply Fund Assessment (SSF)	178,058,636	45.1%&
Other Research Services	13,432,885	3.4%&
Other OD	0	0.0%&
Total NCI Management Fund & SSF	\$394,852,398	100%

MANAGEMENT FUND & SSF SUBTOTALS

Туре	Amount	Percent	
NCI	\$394,852,398	19.9%&	
Other NIH Institutes	\$1,589,193,079	80.1%&	
Total NIH Management Fund & SSF	\$1,984,045,477	100%	

Special Sources of Funds

Cooperative Research and Development Agreements (CRADAs)

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Under a CRADA, the NIH laboratory can provide personnel, services, facilities, equipment or other resources and the collaborator can provide funds, personnel, services, facilities, equipment or other material and/or technical resources. Importantly, the CRADA provides the non-Federal party the option to negotiate an exclusive license to the resultant CRADA Subject Invention(s). The CRADA is the primary legal mechanism the Federal government has to convey such rights in advance of an invention. The agreement has no mandatory length but often are written for 1 to 3 years, renewable at the mutual agreement of the parties.

CRADA RECEIPTS DEPOSITED TO THE U.S. TREASURY

(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2006	13,567	6,142	7,125
2007	12,584	9,410	8,360
2008	13,634	6,677	7,200
2009	13,111	5,466	4,765
2010	13,813	5,024	5,644
2011	13,150	8,582	5,894
2012	15,504	9,253	5,668
2013	10,587	11,226	8,470
2014	21,173	9,334	5,672
2015	24,835	15,772	11,670
2016	28,276	23,411	17,259

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2017	40,647	27,033	20,990
2018	46,311	28,601	22,936
2019	50,978	32,899	28,178

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to support employees of the laboratory, further scientific exchange, and provide education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH. Royalties may be spent in the year of receipt and for two additional fiscal years.

NCI ROYALTY INCOME FUNDING HISTORY

(Dollars in Thousands)

Years	Collections*	Inventor Payments	Other Obligations
2006/2008	29,811	6,853	22,958
2007/2009	36,344	7,210	29,134
2008/2010	50,269	8,192	42,077
2009/2011	51,621	10,225	41,396
2010/2012	58,515	5,729	52,786
2011/2013	69,155	23,271	45,884
2012/2014	84,876	33,279	51,597

Years	Collections*	Inventor Payments	Other Obligations
2013/2015	91,324	48,433	42,891
2014/2016	112,668	33,487	79,181
2015/2017	122,037	30,605	91,432
2016/2018	115,096	27,316	87,780
2017/2019	112,611	27,233	85,378
**2018/2020	85,815	12,500	73,315
**2019/2021	60,596	10,000	50,596

^{*} Collections do not inclue assessments by NIH.

^{** 2018/2020} and 2019/2021 Inventor Payments and Other Obligations are estimates.

Stamp Out Breast Cancer Act

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997 and has since been extended in July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), December 2011 (PL 112-80), December 2015 (PL 114-99) and recently until December 2027 (PL 116-92). This act allows postal customers the opportunity to contribute funds to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service (USPS). Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2019, NCI has received \$62,165,396. NCI uses these funds for research projects directed towards breast cancer research. Thus far, five major programs have been funded, including the Insight Awards to Stamp Out Breast Cancer, the Breast Cancer Research Stamp Exceptional Opportunities Program, the Breast Cancer Premalignancy Program, a clinical trial to determine the risk of breast cancer recurrence, the Molecular and Cellular Characterization of Screen Detected Lesions Consortium, the Breast Cancer Weight Loss (BWEL), and the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). In FY 2019, \$2,517,666 million in Stamp funds were obligated towards Breast Cancer research.

NCI BREAST CANCER STAMP FUNDING HISTORY

(Dollars in Thousands)

FY	Collected	Obligated	*Balance
1999	4,150	0	4,150
2000	3,101	3,499	3,753
2001	5,556	4,846	4,463
2002	3,595	1,129	6,929
2003	5,176	3,130	8,975
2004	4,814	3,472	10,317
2005	4,372	2,987	11,703
2006	4,468	6,896	9,274
2007	3,006	1,601	10,679

FY	Collected	Obligated	*Balance
2008	4,856	2,122	13,413
2009	3,403	1,873	14,944
2010	2,345	2,590	14,698
2011	2,049	1,977	14,770
2012	1,623	1,654	14,738
2013	1,404	1,337	14,805
2014	1,160	1,477	14,488
2015	1,251	1,635	14,105
2016	1,707	1,654	14,158
2017	1,387	1,640	13,905
2018	1,294	5,349	16,497
2019	1,450	2,518	15,429

^{*} Balance includes carryover funds from the prior fiscal year that have not obligated.

Funding for Research Areas

The National Cancer Institute reports how appropriated funds are spent based on different categories or classifications, including specific cancer sites, cancer types, diseases related to cancer, as well as types of NCI research mechanisms. The table below identifies funding levels for frequently requested areas of cancer research.

The research areas in this table do not represent the entire NCI research portfolio. Moreover, funding for research areas often overlap, and therefore the total for all research areas does not add to the total NCI budget. For example, funding for a clinical trial on breast cancer would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine, and ovarian cancers, and relevant amounts would be included in the amounts for all three areas of cancer research.t

FUNDING BY RESEARCH AREAS

(Dollars in Millions)

Disease Area	2013 Actual	2014 Actual	2015 Actual	2016 Actual	2017 Actual	2018 Actual
Total NCI Budget	\$4,789.0	\$4,932.4	\$4,952.6	\$5,206.2	\$5,636.4	\$5,927.7
AIDS	261.6	269.2	269.7	266.4	249.0	241.2
Brain & CNS	176.8	180.4	204.8	196.3	219.8	220.9
Breast Cancer	559.2	528.5	543.6	519.9	544.9	574.9
Cervical Cancer	63.5	71.1	57.1	65.6	68.8	71.5
Clinical Trials	676.5	749.8	748.0	801.0	806.6	895.7
Colorectal Cancer	239.0	223.0	209.3	212.2	208.4	256.0
Head & Neck Cancers	40.6	57.1	60.2	58.9	46.4	62.4
Hodgkin Disease	14.7	15.4	13.6	12.8	13.0	13.3
Leukemia	235.3	236.7	246.9	241.0	250.5	258.3

Disease Area	2013 Actuals	2014 Actuals	2015 Actuals	2016 Actuals	2017 Actuals	2018 Actuals
Liver Cancer	64.5	60.0	70.3	75.7	72.7	95.9
Lung Cancer	287.6	254.1	255.8	283.8	320.6	350.1
Melanoma	122.7	126.2	132.8	142.9	153.2	158.4
Multiple Myeloma	45.5	46.6	48.9	52.1	60.7	61.5
Non-Hodgkin Lymphoma	113.9	118.0	122.4	116.7	119.5	121.0
Ovarian Cancer	101.0	91.5	92.8	95.6	110.1	120.8
Pancreatic Cancer	102.0	122.4	125.3	152.6	178.3	182.1
Prostate Cancer	256.3	217.8	228.9	241.0	233.0	239.3
Stomach Cancer	11.2	11.3	13.5	13.3	13.4	14.2
Uterine Cancer	17.9	15.5	13.0	16.8	17.5	17.5

The figures in this table were created using NCI's coding methodology. More information about this methodology, as well as the research projects associated with these and other disease area categories, are available on the NCI Funded Research Portfolio website.

The FY 2018 funds available to the NCI totaled \$5.94 billion (includes \$300 million in CURES Act funding), reflecting a increase of 5 percent, or \$284 million from the previous fiscal year. Under the NCI RPG funding policy for FY 2018, non-competing grants were awarded at 100 percent of the committed level. For more information on NCI's grant funding policy, visit the NCI Division of Extramural Activities website.

NCI Extramural Programs

The NCI uses most of its budget to fund extramural grants and contracts. The following links provide information about Fiscal Year 2018 extramural funding by grant activity, institution, state, and country.

Research Project Grants (RPGs)

During fiscal year 2019,&

- Over 73% of competing dollars supported grants awarded within the established payline and RFAs and the remainder supported grants as an exception to the fundable range.
- RFA funds accounted for 17.6% of the FY 2019 competing dollars.&
- A total of 1,178 competing RPGs were funded.

FY 2019 data on this page includes FY 2019 Cures-Moonshot funding and excludes FY 2017 and 2018 Cures-Moonshot carryover obligations.

Number of RPG Awards



^{*}Includes Small Business Innovation Research and Small Business Technology Transfer Awards. Fiscal years 2017, 2018, and 2019 includes Cancer Moonshot funding.

RPGs Summary, FY 2018-2019

RPG AWARDS FUNDED

(Dollars in Thousands)

RPG Awards Funded	2018 No. or %	2018 Amount	2019 No. or %	2019 Amount
Total Funding for RPGs	4,780	\$2,450,558	4, 984	2,541,700
SBIR/STTR	280	\$142,899	245	136,670
Funding for RPGs without SBIR/STTR Program	4,500	\$2,307,659	4, 739	2,405,030
Continuation or Noncompeting Grants Funded	3,338	\$1,615,654	3,561	1,716,055
Competing Grants Funded	1,162	\$571,222	1,178	572,716
Administrative Supplements	280	\$36,754	268	30,715
Partial Assessment for DHHS Program Evaluation		\$84,028		85,543

FUNDS SET ASIDE WITHIN COMPETING DOLLARS

(Dollars in Thousands)

Grant Category	R01 or Share	2018 No. or %	2018 Amount	2019 No. or %	2019 Amount
Grants within		841	\$326,426	805	319,359
Paylines	Traditional R01	534	\$250,668	544	260,317


Grant Category	R01 or Share	2018 No. or %	2018 Amount	2019 No. or %	2019 Amount
RFA Grants		115	\$107,311	118	100,779
	Share of Competing Grant Funds	18.8%&		17.6%&	
Exception Grants		321	\$244,796	373	253,357
	Share of Competing Grant Funds	42.9%&		44.2%&	

COMPETING RPGS

Statistical Measure	2018	2019
Total Competing Application Requests*	10,317	10,108
Funding Success Rate	11%&	12%&
Percentile Funding for R01 Grants	9th & 14th	8th & 14th
Average Cost-Competing	\$492	\$486
Average Reduction from Recommended/ Requested Levels	-13%&	-14%&
*Excludes SBIR/STTR		

FY 2019 figures include FY 2019 Cancer Moonshot funds. FY 2018 figures include FY 2018 Cancer Moonshot funds.

RPGs Funding Mechanisms



The "Other" category includes DP1, DP2, DP5, R00, R37, U01, U19, UH2, UH3, UG3, UA5, R50, UM1, R15, R55 and R56 activities.

GRANT FUNDING PAYLINES

RPG Mechanism	2018	2019	Description
R01 Traditional Grants	9th & 14th	8th & 14th	Percentile
P01 Program Projects*	17% Reduction&	19% Reduction&	SPL Selected*
R03 Small Grants	25	25	Impact Score
R15 Academic Research	25	25	Impact Score
R21 Exploratory Phase I	7th	7th	Percentile
R33 Exploratory Phase II*	N/A	N/A	SPL Selected*
R41/R42 STTR	25	22	Impact Score
R43/R44 SBIR	27	29	Impact Score

*SPL = Scientific Program Leaders (NCI)

RPGs Requested and Awarded

The following table displays requested and awarded RPGs and the success rate for fiscal years 2018 and 2019. These numbers include Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) awards. The Download the Data link contains data for the prior ten years.

RPGS REQUESTED, AWARDED, AND SUCCESS RATE

(Dollars in Thousands)

Fiscal Year	Туре	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
	Competing New	10,921	\$4,914,256	1,220	\$546,677	
	Competing Renewal	471	327,711	134	96,208	
2010	Competing Supplement	33	8,382	2	331	44.007
2018	Competing Subtotal	11,425	5,250,349	1,356	643,216	11.9%
	Non- Competing			3,424	1,807,342	
	FY 2018 RPG Total			4,780	\$2,450,558	
	Competing New	10,713	\$4,880,003	1,207	\$545,687	
2019	Competing Renewal	445	332,705	122	90,402	11.9%
	Competing Supplement	28	7,197	7	1,611	

Fiscal Year	Туре	Number Requested	Amount Requested	Number Awarded	Amount Awarded	Success Rate
	Competing Subtotal	11,186	5,219,905	1,336	637,700	
2018	Non- Competing			3,648	1,903,999	11.9%
	FY 2019 RPG Total			4,984	\$2,541,700	


Includes Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) Awards.

Fiscal years 2017, 2018, and 2019 figures includes Cancer Moonshot funding data.

Success rate is the number of awarded grants divided by the number of awards requested.

RPG Awards by Grant Activity Codes

This table displays awarded research project grants (RPG) data by grant activity code and count. Please visit NIH Activity Codes for more information on the descriptions.



RPG AWARDS BY GRANT CODES, FY 2018-2019

(Dollars in Thousands)

Grant Code	2018 Number	2018 Amount	2019 Number	2019 Amount
RO1	3,092	\$1,375,890	3,195	\$1,425,516
DP1	2	2,388	1	1,161
DP2	1	2,711	0	466
DP5	6	2,494	3	1,312

Grant Code	2018 Number	2018 Amount	2019 Number	2019 Amount
P01	85	165,529	95	179,123
R00	103	24,704	109	26,260
R37	66	30,163	99	43,535
U01	285	243,522	306	276,369
U19	2	5,087	2	7,593
UH2	7	1,408	7	1,413
R35	125	118,267	142	129,232
R50	63	10,559	81	13,319
UH3	21	11,275	33	18,797
UA5	0	0	0	0
UM1	33	110,404	27	69,816
UG3	11	5,574	8	4,500
R03	149	12,227	121	9,735
R21	382	74,013	447	85,575
R33	45	17,863	38	14,993
R15	20	8,951	23	10,082
R55	0	0	0	0
R56	2	602	2	689
RC2	0	0	0	0
SBIR/STTR	280	142,899	245	136,670

Grant Code	2018 Number	2018 Amount	2019 Number	2019 Amount
Total	4,780	2,366,530	4,984	\$2,456,156

RPG Activity Codes with a "0" count displayed for No. are grants where NCI co-funded a grant but was not the primary IC funding the award.

Fiscal years 2017, 2018, and 2019 includes Cancer Moonshot funds and excludes carryover obligations for fiscal years 2017 and 2018.&

*From FY 2017 onward, RFAs will be accounted for in the actual grant mechanism categories under which they fall.

Grants to NCI-Designated Cancer Centers

NCI-designated cancer centers a re institutions dedicated to research to develop more effective approaches to prevent, diagnose, and treat cancer. Find an NCI designated cancer center near you and learn about its patient services and research capabilities.

The grant count and amounts include FY 2019 Cancer Moonshot funding and excludes fiscal years 2017 and 2018 Cancer Moonshot obligations.

NCI-DESIGNATED CANCER CENTER TOTALS, FY 2019

(Dollars in Thousands)

Mechanism	Count	Amount
Total P30s	71	\$318,323
Planning Grants (P20s)	18	8,014
Other Cancer Center Grants	0	10,744
Total Cancer Center Grants	89	\$337,082

^{*}Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy, updated each fiscal year with limits based on the cost center and division; this category is to be reported as zero.

NCI-DESIGNATED CANCER CENTERS BY STATE (P30 CORE GRANTS), FY 2019

(Dollars in Thousands)

State	Grantee Institution	Code	Count	Amount
Alabama	University of Alabama at Birmingham	Comprehensive Core	1	\$5,492
Arizona	University of Arizona	Comprehensive Core	1	4,117
	Burnham Institute for Medical Research	Basic Core	1	4,075
	City of Hope/ Beckman Research Institute	Comprehensive Core	1	3,315
	Salk Institute for Biological Studies	Basic Core	1	3,067
California	Stanford University	Comprehensive Core	1	4,253
California	University of California Davis	Comprehensive Core	1	3,337
	University of California Irvine	Comprehensive Core	1	4,295
	University of California Los Angeles	Comprehensive Core	1	4,295
	University of California San Diego	Comprehensive Core	1	5,580

State	Grantee Institution	Code	Count	Amount
California	University of California San Francisco	Comprehensive Core	1	8,526
	University of Southern California	Comprehensive Core	1	6,578
Colorado	University of Colorado Denver	Comprehensive Core	1	4,316
Connecticut	Yale University	Comprehensive Core	1	4,840
District of Columbia	Georgetown University	Comprehensive Core	1	2,416
Florida	H. Lee Moffitt Cancer Center & Research Institute	Comprehensive Core	1	3,201
	University of Miami School of Medicine	Comprehensive Core	1	2,149
Georgia	Emory University	Comprehensive Core	1	3,384
Hawaii	University of Hawaii at Manoa	Clinical Core	1	2,141
Illinois	Northwestern University at Chicago	Comprehensive Core	1	7,075
	University of Chicago	Comprehensive Core	1	4,818

State	Grantee Institution	Code	Count	Amount
Indiana	Indiana Univ- Purdue Univ at Indianapolis	Clinical Core	1	2,760
	Purdue University West Lafayette	Basic Core	1	1,860
Iowa	University of Iowa	Comprehensive Core	1	2,912
Kansas	University of Kansas Medical Center	Clinical Core	1	2,373
Kentucky	University of Kentucky	Clinical Core	1	2,475
Maine	Jackson Laboratory	Basic Core	1	850
	Johns Hopkins University	Comprehensive Core	1	7,331
Maryland	University of Maryland Baltimore	Comprehensive Core	1	2,466
	Dana-Farber Cancer Institute	Comprehensive Core	1	13,053
Massachusetts	Massachusetts Institute of Technology	Basic Core	1	3,573

State	Grantee Institution	Code	Count	Amount
Michigan	University of Michigan at Ann Arbor	Comprehensive Core	1	7,041
	Wayne State University	Comprehensive Core	1	3,227
	Mayo Clinic in Rochester	Comprehensive Core	1	5,893
Minnesota	University of Minnesota Twin Cities	Comprehensive Core	1	4,264
Missouri	Washington University	Comprehensive Core	1	4,756
Nebraska	University of Nebraska Medical Center	Clinical Core	1	2,107
New Hampshire	Dartmouth College	Comprehensive Core	1	3,801
New Jersey	Rutgers Cancer Institute of New Jersey	Comprehensive Core	1	3,037
New Mexico	University of New Mexico	Comprehensive Core	1	2,646
New York	Albert Einstein College of Medicine Yeshiva University	Clinical Core	1	2,917

State	Grantee Institution	Code	Count	Amount
	Cold Spring Harbor Laboratory	Basic Core	1	4,404
	Columbia University Health Sciences	Comprehensive Core	1	4,158
	Ichan School of Medicine at Mount Sinai	Clinical Core	1	2,623
New York	Memorial Sloan- Kettering Institute for Cancer Res	Comprehensive Core	1	14,112
	New York University School of Medicine	Clinical Core	1	4,107
	Roswell Park Cancer Institute Corp	Comprehensive Core	1	4,981
	Duke University	Comprehensive Core	1	6,248
North Carolina	University of North Carolina Chapel Hill	Comprehensive Core	1	7,618
	Wake Forest University Health Sciences	Comprehensive Core	1	3,413
Ohio	Case Western Reserve University	Comprehensive Core	1	5,598

State	Grantee Institution	Code	Count	Amount
Ohio	Ohio State University	Comprehensive Core	1	5,385
Oklahoma	University Of Oklahoma Health Sciences Center	Clinical Core	1	2,782
Oregon	Oregon Health and Science University	Comprehensive Core	1	2,819
	Fox Chase Cancer Center	Comprehensive Core	1	3,305
	Thomas Jefferson University	Clinical Core	1	2,874
Pennsylvania	University of Pennsylvania	Comprehensive Core	1	8,203
	University of Pittsburgh at Pittsburgh	Comprehensive Core	1	5,439
	Wistar Institute	Basic Core	1	2,843
South Carolina	Medical University of South Carolina	Clinical Core	1	2,190
Tonnocces	St. Jude Children's Research Hospital	Comprehensive Core	1	6,323
rennessee	Tennessee Vanderbilt Comprehensive University Core	•	1	6,252
Texas	Baylor College of Medicine	Comprehensive Core	1	3,203

State	Grantee Institution	Code	Count	Amount
Texas	University of Texas M.D. Anderson Cancer Center	Comprehensive Core	1	11,232
	University of Texas San Antonio Health Science Center	Clinical Core	1	2,195
	University of Texas Southwestern Medical Center	Comprehensive Core	1	2,681
Utah	University of Utah	Clinical Core	1	2,886
	University of Virginia Charlottesville	Comprehensive Core	1	3,202
Virginia	Virginia Commonwealth University	Clinical Core	1	2,441
Washington	Fred Hutchinson Cancer Research Center	Comprehensive Core	1	10,306
Wisconsin	University of Wisconsin	Comprehensive Core	1	5,863
Total Cancer Centers			89	\$337,082

Specialized Programs of Research Excellence (SPOREs)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). Each SPORE focuses on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. Total funding shown represents the SPORE program using relevant P50s, P20s, U54s, and co-funded grants external to NCI.

The Translational Research Program (TRP) is the home of the SPOREs, a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis, and treatment of human cancers. For more information on these SPORE grants and organ sites, please visit the Translational Research Program.

The NCI Funded Research Portfolio (NFRP) web site contains additional information about the SPORE grants listed below that have been funded by NCI. The NFRP provides access to various NCI budget reports that contain information about research funding according to specific research categories. For more detailed information on all SPORE grants, please visit the NCI Funded Research Portfolio.

FY 2019 FUNDING FOR SPORE GRANTS

(Whole Dollars)


Mechanism	Site	Amount
	Bladder	\$2,138,849
	Brain	13,195,944
	Breast	9,296,715
	Cervical	1,279,343
	Endometrial	2,090,228
	Gastrointestinal (GI)	9,419,551
	GI (Colorectal & Pancreatic Cancers)	2,325,000
	Head and Neck	1,777,841
	Kidney	4,277,019
P50 SPOREs	Leukemia	5,970,645
	Liver	4,654,`107
	Lung	7,589,329
	Lymphoma	9,428,795
	Melanoma	4,146,656
	Myeloma	4,396,947
	Neuroendocrine	2,139,000
	Ovarian	5,361,678
	Pancreatic	2,134,321
	Prostate	14,382,308

Mechanism	Site	Amount
	Sarcoma	2,126,449
P50 SPOREs	Skin	2,324,892
	Thyroid	0
	Subtotal	\$110,445,617
U54 SPOREs	Hyperactive RAS	\$2,124,182
U34 SPURES	Subtotal	\$2,124,182
Co-funded	Head & Neck	\$216,200
Co-iunded	Total Co-funded	\$216,200
Total Number of SPOREs, Total SPOR	\$112,795,999	

Dr. Ruth L. Kirschstein National Research Service Awards (NRSA)

This trainee award program is named after Dr. Ruth L. Kirschstein, a polio vaccine researcher and a champion of research training and inclusion of underrepresented individuals in the scientific workforce. Dr. Kirschstein was the first woman to become director of an NIH institute.&


The NCI Ruth L. Kirschstein National Research Service Award (NRSA) program helps ensure that a diverse pool of highly trained scientists is available in appropriate scientific disciplines to meet the Nation's biomedical, behavioral, and clinical research needs.



Data for fiscal years 2014 and 2015 in previous editions of the NCI Budget Fact Book reported the total number of "Individual" and "Institutional" awards instead of the total number of Predoctoral and Postdoctoral full-time training positions. This table has been updated with the correct data.


Research Career Awards "K" Program

The NCI career development (K) awards program includes a broad range of funding mechanisms and provides scientists with support to further develop their cancer research careers, transition to independence, expand their existing research programs, or mentor junior investigators. The K awards are a significant component of NCI's training effort.&



Percent of Total Research Career Awards Funded

Fiscal Year 2019



- K00 Post-Doc-Fellow Awards
- K01 Research Scientist Development Award
- K05 Research Scientist Award
- K07 Preventive Oncology
- K08 Clinical Investigator
- K12 Institutional Clinical Oncology Research
- K22 Transitional Career Development
- K23 Patient-Oriented Career
- K24 Patient-Oriented Career Mid Career
- K25 Mentored Quantitative Research Career Development Award
- K43 Mentored Career Devel/Temin Intl Career
- K99 NIH Pathway to Independence Awards

cancer.gov

Grant and Contract Awards

The following displays the number and dollar amount of grant and contract awards by state and country with details for institutions receiving more than \$15 million in support from NCI.


Grants are used when no substantial programmatic involvement is anticipated between the NCI and the grant recipient during performance of the financially assisted activities and when there is no expectation on the part of the NCI of a specified service or product for NCI.&

Contract are used to procure cancer research services and other resources that the Federal government needs to advance the NCI cancer research mission.

Grant and contract data includes FY 2019 Cancer Moonshot funds and excludes FYs 2017 and 2018 Cancer Moonshot carryover obligations, Breast Cancer Stamp, NRSA tap, the Loan Repayment Program, Program Evaluation, and other assessments. Per the National Institutes of Health's Office of Extramural Research (OER) "Count Rules" & guidelines policy are updated each fiscal year with limits based on the cost center and division. A "0" indicates an award funded by other NIH Institutes that NCI also co-funded.

Grant and Contract Awards by State and Institution

In the map graphic below, grant and contract awards are presented by state. The table below the graphic provides information for U.S. territories. Within each state, hover to view the total amount awarded and click to view detailed data on institutions that received more than \$15 million in support from NCI during FY 2019. For purposes of the Fact Book, institutions include universities, cancer centers, and hospitals.



Other category represents total grant and contract funding in that state for all remaining organizations including universities, cancer centers, and hospitals who receive less than \$15 million in NCI support.

GRANT AND CONTRACT AWARDS BY STATE, FY 2019

(Whole Dollars)

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Alabama	63	\$32,036,913	3	\$666,907	66	\$32,703,820
Arizona	59	37,531,259	1	1,267,397	60	38,798,656

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Arkansas	14	5,186,322	0	0	14	5,186,322
California	898	505,460,287	23	22,659,474	921	528,119,761
Colorado	91	34,792,933	2	2,299,989	93	37,092,922
Connecticut	106	52,640,196	4	5,863,644	110	58,503,840
Delaware	10	7,293,873	0	0	10	7,293,873
District Of Columbia	65	30,717,894	19	20,330,493	84	51,048,387
Florida	189	84,043,318	3	1,186,589	192	85,229,907
Georgia	109	46,660,508	33	5,929,210	142	52,589,718
Hawaii	18	12,817,922	1	1,847,682	19	14,665,604
Idaho			1	608,511	1	608,511
Illinois	261	122,563,413	9	3,537,698	270	126,101,111
Indiana	76	30,461,863	0	219,814	76	30,681,677
Iowa	33	21,550,698	2	4,596,776	35	26,147,474
Kansas	26	11,998,336	0	0	26	11,998,336
Kentucky	50	21,246,792	2	3,746,725	52	24,993,517
Louisiana	33	14,444,448	1	1,865,938	34	16,310,386
Maine	12	5,873,691	0	0	12	5,873,691
Maryland	170	89,796,462	44	579,137,174	214	668,933,636
Massachusetts	688	387,250,776	8	992,491	696	388,243,267
Michigan	216	102,526,223	4	523,107	220	103,049,330

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Minnesota	163	109,017,613	4	2,869,904	167	111,887,517
Mississippi	3	356,314	0	0	3	356,314
Missouri	131	68,997,217	90	8,384,317	221	77,381,534
Montana	4	2,570,251	0	0	4	2,570,251
Nebraska	49	20,988,334	17	493,428	66	21,481,762
Nevada	4	1,967,244	0	0	4	1,967,244
New Hampshire	34	18,085,623	1	1,499,588	35	19,585,211
New Jersey	74	32,867,792	3	7,894,468	77	40,762,260
New Mexico	24	13,924,112	1	2,760,430	25	16,684,542
New York	735	382,433,170	5	10,421,080	740	392,854,250
North Carolina	294	154,638,939	3	673,536	297	155,312,475
North Dakota	1	168,537	0	0	1	168,537
Ohio	238	118,977,429	0	159,859	238	119,137,288
Oklahoma	34	15,950,933	2	969,980	36	16,920,913
Oregon	62	51,505,556	20	540,738	82	52,046,294
Pennsylvania	441	316,111,135	56	2,374,112	497	318,485,247
Rhode Island	23	3,830,692	0	0	23	3,830,692
South Carolina	59	27,878,456	0	0	59	27,878,456
South Dakota	3	895,016	2	54,210	5	949,226
Tennessee	165	113,019,327	0	0	165	113,019,327

State	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Texas	523	269,261,009	4	5,905,334	527	275,166,343
Utah	72	27,217,721	2	2,096,616	74	29,314,337
Vermont	9	3,109,791	0	0	9	3,109,791
Virginia	110	53,666,798	8	8,320,715	118	61,987,513
Washington	222	159,115,853	2	5,218,561	224	164,334,414
West Virginia	10	4,465,386	0	0	10	4,465,386
Wisconsin	100	57,597,756	3	1,258,957	103	58,856,713
Subtotal	6,774	3,685,512,131	383	719,175,453	7,157	4,404,687,584
Guam	1	833,216	0	0	1	833,216
Puerto Rico	11	5,246,638	0	0	11	5,246,638
Total	6,786	\$3,691,591,985	383	\$719,175,453	7,169	\$4,410,767,438

Grant and Contract Awards by Country

NCI funds and co-funds cancer research all over the world. The table below lists number and dollar amount of grant and contract awards by country.

GRANT AND CONTRACT AWARDS BY COUNTRY, FY 2019

(Whole Dollars)

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Argentina	1	\$382,564	0	0	1	\$382,564
Australia	3	2,493,988	0	0	3	2,493,988
Belarus	0	0	1	49,394	1	49,394
Canada	10	4,677,202	1	650,265	11	5,327,467
Costa Rica	0	0	1	622,604	1	622,604
Eritrea	1	225,000	0	0	1	225,000
France	3	2,849,664	0	0	3	2,849,664
Germany	1	899,909	0	0	1	899,909
India	0	224,969	0	0	0	224,969
Korea Rep Of	1	54,000	0	0	1	54,000
Netherlands	1	197,457	0	0	1	197,457
Nigeria	0	163,342	0	0	0	163,342
Peru	0	224,955	0	0	0	224,955
Poland	0	0	1	391,150	1	391,150
South Africa	1	77,740	0	0	1	77,740
Sweden	3	489,587	0	0	3	489,587
Switzerland	0	461,468	0	0	0	461,468

Country	No. of Grants	Amount for Grants	No. of Contracts	Amount for Contracts	Total Number	Total Amount
Tanzania U Rep	0	75,000	0	0	0	75,000
United Kingdom	2	324,590	0	0	2	324,590
Zambia	0	80,028	0	0	0	80,028
Total	27	\$13,901,463	4	\$1,713,413	31	\$15,614,876


NCI Historical Trends

Established in 1937, the National Cancer Institute (NCI) was among the first Institutes of the National Institutes of Health (NIH). From the outset, NCI served as a scientific cornerstone of the NIH. The following links provide information about the history of NCI appropriations and the Professional Judgment (Bypass) Budget, as well as data on funding trends and staffing levels.

NCI Professional Judgment Budget and Appropriations

Professional Judgment Budget, President's Budget and Enacted Appropriations Comparison

This graph displays a historical view of the Professional Judgment Budget, the President's Budget, and the Enacted Appropriations for the NCI from fiscal years 1974 through 2020. The National Cancer Act gives the NCI Director special authority to submit an annual Professional Judgment Budget, sometimes referred to as the "Bypass Budget," directly to the President and Congress. This budget reflects NCI cancer research priorities and identifies areas of potential investment in cancer research. The President's Budget is an annual report prepared by the White House, and in coordination with federal agencies, proposing funding levels for the federal government, including for the NIH and NCI, according to the President's priorities. Congress reviews the Professional Judgment Budget and the President's Budget, and then conducts its own inquiries and hearings to develop and pass an appropriations bill to fund the government. When the bill is signed into law by the President, the Enacted Appropriation levels become available for NCI's cancer research activities.



- The Professional Judgment Budget was not released in FY 2014, FY 2015, or in FY 2018. To learn more about this authority and view the budget archive, please visit NCI's About the Annual Plan and Budget Proposal page.
- The FY 2017 and FY 2018 Enacted Appropriated budget includes \$300,000,000 of Cancer MoonshotSM funding. \$400,000,000 and \$195,000,000 of Cancer MoonshotSM funding are included in the FY 2019 and FY 2020 Enacted Appropriated levels, respectively. The Professional Judgment Budget also includes \$400,000,000 and \$195,000,000 of Cancer MoonshotSM funding in fiscal years 2019 and 2020, respectively.
- The Enacted Appropriation levels do not include potential adjustments such as Rescissions, Sequestrations, Supplemental funding, or Secretary's Transfers that may have impacted the amount available for NCI expenditure.

NCI Appropriations

NCI receives its budget from the United States Congress as part of the federal budget process for the Department of Health and Human Services and NIH.

The NCI budget for FY 2019 (October 1, 2018 through September 30, 2019) is \$6.14 billion. During the period from 2009 through 2019, the NCI budget averaged \$5.29 billion per year.

APPROPRIATIONS OF THE NCI, 1938-2019

(Whole Dollars)

Fiscal Years	Amount	Notes
1938 - 2002	\$52,940,982,220	
2003	4,622,394,000	Prior to reductions in PL 108-7(-\$30,046,000 for the enacted rescission and \$2,000 lapse). Includes \$263,442,000 of AIDS funding.
2004	4,770,519,000	Prior to reductions in PL 108-199(-\$3,136,000 for Labor/ HHS/ED rescission; \$28,128,000 for across the board reduction; -\$15,357,000 NIH 1% transfer assessment, and \$5,000 lapse). Includes \$266,975,000 of AIDS funding.
2005	4,865,525,000	Prior to reductions in PL 108-447(\$38,914,000 .8% across the board reduction; -\$1,353,000 for Labor/HHS/ED rescission; -\$30,505,000 NIH 1% transfer assessment, and \$9,000 lapse). Includes \$265,907,000 of AIDS funding.
2006	4,841,774,000	Prior to reductions in PL 109-149 (-\$48,418,000 for Labor/HHS/ED rescission; -\$3,293,000 HHS transfer for CMS activities; -\$42,834,000 NIH 1% transfer for roadmap activities, and \$4,000 lapse). Includes \$253,866,000 of AIDS funding.
2007	4,797,639,000	Prior to reductions in PL 110-5 (-\$5,015,000 NIH transfer for GEI activities, and \$9,000 lapse). Includes \$253,866,000 of AIDS funding.

Fiscal Years	Amount	Notes
2008	4,890,525,000	Prior to -\$85,437,000 rescission and \$3,091,000 in NIH transfer activities. Includes supplemental appropriation of \$25,559,000. Includes \$258,499,000 of AIDS funding.
2009	4,968,973,000	Prior to reductions in PL 111-8 (-\$2,042,631 NIH transfer for activities, and \$4,000 lapse). Includes \$265,882,000 of AIDS funding.
2010	5,103,388,000	Prior to -\$760,000 HHS Secretary's transfer, -\$4,459,000 in NIH transfer for activities, and \$22,000 lapse. Includes \$272,130,000 of AIDS funding.
2011	5,103,388,000	Prior to -\$44,810,787 recission and \$472,000 lapse. Includes \$269,953,000 of AIDS funding.
2012	5,081,788,000	Prior to \$9,605,579 rescission, -\$1,445,000 HHS Secretary's transfer ,-\$3,342,000 HHS Secretary's transfer for Alzheimer's research, and \$54,000 lapse. Includes \$271,692,000 of AIDS funding.
2013	5,072,183,000	Prior to -\$254,589,000 under sequestration (Budget Control Act, 2011, PL 112–25), -\$10,144,367 recission, -\$28,044,000 HHS Secretary's transfer and +\$9,714,000 restored from the National Children's Study and National Eye Institute HIV/AIDS funding, and \$106,000 lapse. Includes \$261,550,000 of AIDS funding.
2014	4,923,238,000	Prior to -\$12,359,000 HHS Secretary's transfer,-\$965,000 HHS Secretary's Cybersecurity Transfer (authorized by section 206 of P.L. 113-76), +\$16,180,552 transfer from National Children's Study, and +\$6,307,000 transfer from NIH Office of AIDS Research, and \$33,000 lapse. Includes \$269,212,000 of AIDS funding.

(Continued from previous page)

Fiscal Years	Amount	Notes
2015	4,950,396,000	Prior to +\$2,632,000 transfer from NIH Office of AIDS Research and \$435,000 lapse. Includes \$269,660,000 of AIDS funding.
2016	5,214,701,000	Prior to -\$7,217,390 HHS Secretary's transfer, -\$1,192,000 transfer to NIH Office of AIDS Research, and \$122,000 lapse. Includes \$266,422,000 of AIDS funding.
2017	5,689,329,000	Prior to -\$11,971,000 HHS Secretary's transfer, -\$17,403,000 transfer to NIH Office of AIDS Research, and \$247,000 lapse. Includes \$249,019,000 of AIDS funding and \$300,000,000 of Cancer Moonshot SM funding.
2018	5,964,800,000	Prior to -\$13,309,000 HHS Secretary's transfer, -\$7,785,000 transfer to NIH Office of AIDS Research, and \$250,000 lapse. Includes \$241,234,000 of AIDS funding and \$300,000,000 of Cancer Moonshot SM funding.
2019	6,143,892,000	Prior to -\$19,730,000 HHS Secretary's transfer, -\$2,874,000 transfer to NIH Office of AIDS Research, and \$252,786 lapse. Includes \$241,979,000 of AIDS funding and \$400,000,000 of Cancer Moonshot SM funding.
1938 - 2019	\$139,945,434,220	

NCI Funding Trends

Funding amounts and percentages reflect actual obligations for each fiscal year.

NCI FUNDING

Funding, FY 2015-2019

(Dollars in Millions)

Mechanism	2015	2016	2017	2018**	2019**
Total NCI	\$4,952.6	\$5,206.2	\$5,636.4	\$5,927.6	\$5,992.3
Research Project Grants	2,092.6	2,146.1	2,278.4	2,450.6	2,541.7
Cancer Centers	288.7	335.0	313.0	331.4	337.1
SPOREs	102.7	108.2	111.4	115.8	110.7
Other P50s/P20s	5.8	2.8	1.3	0	7.4
Specialized Centers	112.3	99.3	135.6	178.3	200.8
Clinical Cooperative Groups	250.8	221.0	245.3	255.3	290.1
R&D Contracts	597.0	732.3	880.4	825.4	768.1
Intramural Research	843.2	894.5	899.7	945.5	964.9
Other Mechanisms*	659.6	666.9	771.2	825.3	771.5

^{*}Other mechanisms includes Research Career Program Cancer Education, Minority Biomedical Research Support, Other Grants, National Research Service Awards (NRSA), Research Management & Support, Buildings & Facilities.

^{**}Includes Cancer Moonshot funding for fiscal years 2017, 2018, and 2019

PERCENT CHANGE BY MECHANISM

Percent Change by Mechanism, FY 2015-2019

Mechanism	2014 to 2015	2015 to 2016	2016 to 2017	2017 to 2018	2018 to 2019
Total NCI	0.4%	5.1%	8.3%	5.2%	1.1%
Research Project Grants	4.0%	2.6%	6.2%	7.6%	3.7%
Cancer Centers	2.4%	16.0%	-6.6%	5.9%	1.7%
SPOREs	-1.8%	5.4%	3.0%	3.9%	-4.4%
Other P50s/P20s	-68.1%	-51.5%	-52.6%	-100.0%	100.0%
Specialized Centers	-19.3%	-11.6%	36.5%	31.5%	12.6%
Clinical Cooperative Groups	-7.7%	-11.9%	11.0%	4.1%	13.6%
R&D Contracts	-8.5%	22.7%	20.2%	-6.2%	-6.9%
Intramural Research	-0.2%	6.1%	0.6%	5.1%	2.1%
Other Mechanisms*	8.7%	1.1%	15.6%	7.0%	-6.5%

^{*}Other mechanisms includes Research Career Program Cancer Education, Minority Biomedical Research Support, Other Grants, National Research Service Awards (NRSA), Research Management & Support, Buildings & Facilities.

PERCENT SHARE OF TOTAL NCI DOLLARS


Mechanism Share of NCI Budget, FY 2015-2019

Mechanism	2015	2016	2017	2018	2019
Research Project Grants	42.3%	41.2%	40.4%	41.3%	42.4%
Cancer Centers	5.8%	6.4%	5.6%	5.6%	5.6%
SPOREs	2.1%	2.1%	2.0%	2.0%	1.8%
Other P50s/P20s	0.1%	0.1%	0.0%	0.0%	0.1%
Specialized Centers	2.3%	1.9%	2.4%	3.0%	3.4%
Clinical Cooperative Groups	5.1%	4.2%	4.4%	4.3%	4.8%
R&D Contracts	12.1%	14.1%	15.6%	13.9%	12.8%
Intramural Research	17.0%	17.2%	16.0%	16.0%	16.1%
Other Mechanisms*	13.3%	12.8%	13.7%	13.9%	12.9%

^{*}Other mechanisms includes Research Career Program Cancer Education, Minority Biomedical Research Support, Other Grants, National Research Service Awards (NRSA), Research Management & Support, Buildings & Facilities.

Extramural vs Intramural and RMS Funding

The following is a comparison broken out by mechanism and total between Extramural dollars spent vs Intramural Research Program (IRP) and Research Management and Support (RMS).



Includes FY 2019 Cures-Moonshot funding.

Excludes FY 2017 and FY 2018 Cures-Moonshot carryover obligations.

FY 2015-2019 EXTRAMURAL FUNDING

(Dollars in Millions)

Mechanism	2015	2016	2017	2018	2019	2015- 2019 % Change
Research Project Grants	\$2,092.6	\$2,146.1	\$2,278.4	\$2450.6	\$2,541.7	21.5%
Cancer Centers	288.7	335.0	313.0	331.4	337.1	16.8%
SPOREs	102.7	108.2	111.4	115.8	110.7	7.8%
Other P50s/ P20s	5.8	2.8	1.3	0.0	7.4	28.0%
Other Specialized Centers	112.3	99.3	135.6	178.3	200.8	78.8%
Other Research Grants	410.1	399.1	481.9	537.9	506.8	23.6%
NRSA	69.8	73.0	77.6	82.4	87.0	24.6%
R&D Contract	597.0	732.3	880.4	825.4	768.1	28.7%
Buildings & Facilities	8.0	16.0	30.0	18.0	18.0	125.0%
Total Extramural Funds	\$3,687.0	\$3,911.9	\$4,309.7	\$4,539.8	\$4,577.5	24.2%

FY 2015-2019 INTRAMURAL AND RMS FUNDING

(Dollars in Millions)

Mechanism	2015	2016	2017	2018	2019	2015- 2019 % Change
Intramural Research	\$843.2	\$894.5	\$899.7	\$945.5	\$964.9	14.4%
RMS	422.5	399.8	427.0	442.4	449.9	6.5%
Total IRP & RMS Funds	\$1,265.6	\$1,294.3	\$1,326.7	\$1,387.9	\$1,414.8	11.8%

FY 2015-2019 TOTAL NCI FUNDING

(Dollars in Millions)

2015	2016	2017	2018	2019	2015-2019 % Change
\$4,952.6	\$5,206.2	\$5,636.4	\$5,927.7	\$5,992.3	21.0%


Comparison of Dollars, Positions, and Space

This page presents tables comparing of NCI's budget, full-time equivalent (FTE) positions, and occupied space from fiscal years 2010 through 2019.

In this table, funds represent obligations against the annual appropriation in millions of dollars. Fiscal years 2017, 2018, and 2019 amounts include the Cancer MoonshotSM funding. FTEs are the number of work years for appointed employees of the NCI. A work year equals 2,080 hours. Space is in thousands of square feet, excluding NCI-Frederick.

The increase in space (Sq Ft) during FY 2013 is due to NCI's lease of its Shady Grove complex, a new consolidated facility in Rockville, MD. This facility has the advantage of providing additional space for NCI scientific programs, and includes conference and meeting rooms, a cafeteria, and a data center that serves multiple NCI facilities. During FY 2013, NCI was working to decommission their vacated leased facilities, and continued to lease a portion of them while completing the decommissioning process.

The 2016 FTE count has been updated to include Commissioned Corp staff.



NCI Personnel

The table below displays NCI-staffing levels, by type of appointment, for fiscal years 2009-2019.

- Full-time equivalents represent 2,080 hours per person employed
- Full-time and part-time appointments include employees from NIH Employment Report 71E
- Training Fellows including visiting fellows, Cancer Research Training Award (CRTA) and the few remaining Intramural Research Training Award (IRTA), biotech, and tech transfers
- Total employees include full-time and part-time permanent tours


NCI PERSONNEL, FY 2009-2019

Fiscal Year	Full Time Permanent	Other Than Full Time Permanent	Training Fellows	Total Personnel Resources
2009	2,118	959	1,058	4,135
2010	2,148	1,011	1,073	4,232
2011	2,180	1,029	1,108	4,317
2012	2,139	997	906	4,042
2013	2,173	948	847	3,968
2014	2,139	923	879	3,941
2015	2,119	897	947	3,963
2016	2,050	1,001	972	4,023
2017	2,156	890	1,042	4,088
2018	2,083	845	1,045	3,973
2019	2,101	879	1,061	4,041

NCI and NIH AIDS Funding History

The NCI has played a major role in HIV/AIDS research since the beginning of the AIDS epidemic. Scientists within and supported by the NCI have made a number of key discoveries. HIV/AIDS research is conducted throughout the Divisions and Offices of the NCI and is coordinated by the NCI Office of HIV and AIDS Malignancy.

In addition, because HIV/AIDS transcends every area of clinical medicine and basic scientific investigation, the NIH AIDS research effort involves every NIH Institute and Center. The NIH Office of AIDS Research has primary responsibility for planning and coordinating AIDS research across the NIH.



Cancer MoonshotSM - Recent Fiscal Year Funding

The 21st Century Cures Act, which was signed into law in December 2016, authorized \$1.8 billion to fund the Cancer Moonshot over a 7 year period. The goal of the Cancer Moonshot is to accelerate progress in cancer, including prevention and screening, from cutting edge basic research to wider uptake of standard of care.

The following pages contain information on the \$400 million of Cancer Moonshot funding received during Fiscal Year 2019.

More information on Cancer Moonshot can be found by visiting the NCI Cancer Moonshot Initiative page.

Information on recent funding opportunity announcements can be found on the Cancer Moonshot Funding Opportunities page.

CANCER MOONSHOT FISCAL YEAR SUMMARY


(Whole Dollars)

Fiscal Year	Authorization
2017	\$300,000,000
2018	\$300,000,000
2019	\$400,000,000
2020	\$195,000,000
2021	\$195,000,000
2022	\$194,000,000
2023	\$216,000,000
Total	\$1,800,000,000

Funding for the Cancer Moonshot is appropriated on an annual basis. The following pages contain information on the initial \$195 million of Cancer Moonshot funding received during Fiscal Year 2019.

Cancer MoonshotSM - Obligations by Budget Mechanism

With \$258 million appropriated for Cancer Moonshot activities in fiscal year (FY) 2019, funding was allocated into four budget mechanisms: research grants, R&D contracts, intramural research, and research management and support, as shown in the chart below.



Similar to the institute's annual appropriation, NCI reports Cancer Moonshot obligations by funding mechanism.

FY 2019 CANCER MOONSHOT AND CARRYOVER - OBLIGATIONS BY MECHANISM

(Whole Dollars)

Type of Mechanism	Mechanism	Number	Amount¹
	Competing	37	\$40,645,830
	Noncompeting	17	\$52,771,539
Research Project Grants (RPGs)	Administrative Supplements	16	\$2,799,992
(RPGS)	Subtotal, without SBIR	54	\$96,217,361
	SBIR/STTR Grants	3	\$2,206,927
	Subtotal, RPGs	57	\$98,424,288
	Cancer Centers Grants- P30s	0	\$7,458,939
Centers	P50s	6	\$7,423,937
Centers	Cooperative Agreements-U54s	19	\$81,472,077
	Subtotal, Centers	25	\$96,354,953
	Resource Grants-U24s	6	\$13,510,468
Other Research	Subtotal, Other Research	6	\$13,510,468
Subtotal, Research Grants		88	\$208,289,709
Intramural Research		0	\$19,695,532
Research Management & Support		0	\$128,645

(Continued from previous page)

Type of Mechanism	Mechanism	Number	Amount¹
	R&D Contracts	6	\$17,639,644
R&D Contracts	SBIR/STTR Contracts	18	\$12,598,651
	Subtotal, R&D Contracts	27	\$30,238,295
Total			\$258,352,183

¹ Includes new obligations and recoveries from FY 2017 and FY 2018 carryover accounts.

Cancer MoonshotSM - Funding by Research Category

To ensure the Cancer Moonshot goals and approaches were grounded in the best science, NCI convened a Blue Ribbon Panel (BRP) of scientific experts as a working group to the National Cancer Advisory board. In September of 2016, the BRP presented a final report outlining 10 research recommendations that represent areas that are well-positioned to accelerate progress in cancer prevention, diagnosis, treatment and care.

The following research categories align with these 10 recommendations:

CANCER MOONSHOT BY CATEGORY, FY 2019

(Whole Dollars)

Research Category	Amount¹
Network for Direct Patient Engagement	\$(8,795,704)
Cancer Immunotherapy Translational Science Network	\$86,782,365
Therapeutic Target Identification to Overcome Drug Resistance	\$10,028,909
A National Cancer Data Ecosystem for Sharing and Analysis	\$9,547,537
Fusion Oncoproteins in Childhood Cancers	\$38,016,479
Minimize Cancer Treatment's Debilitating Side Effects	\$6,872,822
Prevention and early detection: Implementation of Evidence-Based Approaches	\$65,799,925
Retrospective Analysis of Biospecimens form Patients Treated with Standard of Care	\$-
Generation of Human Tumor Atlases	\$16,440,536
Development of New Enabling Cancer Technologies	\$33,547,913

(Continued from previous page)

Research Category	Amount¹
Other Cancer Moonshot priority activities (e.g., Partnership for Accelerating Cancer Therapies)	\$111,401
Total	\$258,352,183
¹ Includes new obligations and recoveries from FY 2017 and FY 2018 carryover accounts.	



cancer.gov